Ropinirole in the Treatment of Bipolar Depression
April 17, 2017 updated by: Cambridge Health Alliance
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder
To demonstrate efficacy and safety of Requip in in treating bipolar depression.
Study Overview
Detailed Description
This study is 8 weeks long, with an optional additional 8 weeks.
The study is placebo-controlled and patients are randomized to receive either ropinerol or placebo.
Changes in depression, anxiety and overall psychiatric symptoms will be monitored during participation.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02139
- Cambridge Health Alliance
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meet DSM-IV criteria for bipolar disorder
- Current MADRS score > 16
- Current MRS-SADS score < 10
- Prior to participation in this study, each subject must sign an informed consent.
- All patients will be required to also take at least one other mood-stabilizing agent, defined as a standard agent (lithium, valproate, carbamazepine) or a novel anticonvulsant agent (oxcarbazepine, gabapentin, topiramate). If patients are not taking any of these agents on study initiation, they will be required to start one of these agents at study initiation. Study inclusion criteria must be met after at least 2 weeks of treatment with one of these mood-stabilizing agents.
Exclusion Criteria:
- Any serious acute medical illness
- Any clinically serious evidence of suicidality or score of 3 or greater on suicide item on MADRS scale
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Primary outcome will be group differences between Requip and placebo in random effects linear regression analysis.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
The secondary outcomes will include predictors of response, such as insight into illness, comorbid anxiety symptoms, prior course of illness, previous treatment history with antidepressants, and other relevant clinical and demographic features.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert T Dunn, MD,PhD, Cambridge Health Alliance
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2005
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
March 17, 2008
Study Registration Dates
First Submitted
April 13, 2006
First Submitted That Met QC Criteria
April 13, 2006
First Posted (Estimate)
April 17, 2006
Study Record Updates
Last Update Posted (Actual)
April 18, 2017
Last Update Submitted That Met QC Criteria
April 17, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHA-IRB-0116/05/05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.